We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Apyx Medical (APYX - Free Report) closed the most recent trading day at $7.78, moving -0.51% from the previous trading session. This change lagged the S&P 500's daily gain of 1.09%. At the same time, the Dow added 0.84%, and the tech-heavy Nasdaq gained 1.42%.
Prior to today's trading, shares of the medical device maker had lost 8% over the past month. This has lagged the Medical sector's gain of 1.58% and the S&P 500's gain of 1.18% in that time.
Investors will be hoping for strength from APYX as it approaches its next earnings release. In that report, analysts expect APYX to post earnings of -$0.19 per share. This would mark a year-over-year decline of 533.33%. Meanwhile, our latest consensus estimate is calling for revenue of $5.83 million, down 41.23% from the prior-year quarter.
APYX's full-year Zacks Consensus Estimates are calling for earnings of -$0.71 per share and revenue of $25.51 million. These results would represent year-over-year changes of -144.83% and -17.68%, respectively.
Investors should also note any recent changes to analyst estimates for APYX. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 71.95% lower. APYX is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 76, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know
Apyx Medical (APYX - Free Report) closed the most recent trading day at $7.78, moving -0.51% from the previous trading session. This change lagged the S&P 500's daily gain of 1.09%. At the same time, the Dow added 0.84%, and the tech-heavy Nasdaq gained 1.42%.
Prior to today's trading, shares of the medical device maker had lost 8% over the past month. This has lagged the Medical sector's gain of 1.58% and the S&P 500's gain of 1.18% in that time.
Investors will be hoping for strength from APYX as it approaches its next earnings release. In that report, analysts expect APYX to post earnings of -$0.19 per share. This would mark a year-over-year decline of 533.33%. Meanwhile, our latest consensus estimate is calling for revenue of $5.83 million, down 41.23% from the prior-year quarter.
APYX's full-year Zacks Consensus Estimates are calling for earnings of -$0.71 per share and revenue of $25.51 million. These results would represent year-over-year changes of -144.83% and -17.68%, respectively.
Investors should also note any recent changes to analyst estimates for APYX. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 71.95% lower. APYX is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 76, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.